Compare · NAUT vs WAT
NAUT vs WAT
Side-by-side comparison of Nautilus Biotechnology Inc. (NAUT) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAUT and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $40.72B, about 363.1x NAUT ($112.2M).
- WAT has been more active in the news (6 items in the past 4 weeks vs 1 for NAUT).
- WAT has more recent analyst coverage (25 ratings vs 7 for NAUT).
- Company
- Nautilus Biotechnology Inc.
- Waters Corporation
- Price
- -
- -
- Market cap
- $112.2M
- $40.72B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- 1995
- News (4w)
- 1
- 6
- Recent ratings
- 7
- 25
Nautilus Biotechnology Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the human proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company is headquartered in Seattle, Washington.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest NAUT
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- SEC Form 10-Q filed by Nautilus Biotechnology Inc.
- Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
- Nautilus Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- SEC Form 4 filed by Director Posard Matthew L.
- SEC Form 4 filed by Director Akinsanya Karen
- SEC Form 4 filed by Director Nazem Farzad
- SEC Form 4 filed by Director Mcilwain Matthew S
Latest WAT
- SEC Form 8-K filed by Waters Corporation
- SEC Form 10-Q filed by Waters Corporation
- Director Kuebler Christopher A sold $1,442,930 worth of shares (3,626 units at $397.94) and exercised 3,626 shares at a strike of $136.43 (SEC Form 4)
- Waters upgraded by TD Cowen with a new price target
- Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition
- Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
- Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
- RBC Capital Mkts initiated coverage on Waters with a new price target
- Director Knight Heather was granted 63 shares, increasing direct ownership by 5% to 1,281 units (SEC Form 4)
- Director Jiang Wei was granted 67 shares, increasing direct ownership by 2% to 3,573 units (SEC Form 4)